NCT05988697View on ClinicalTrials.gov

Evaluate the Efficacy and Safety of Aspirin in Combination With Trametinib and Dabrafenib

Not yet recruitingOBSERVATIONAL
Enrollment

36

Participants

Timeline

Start Date

November 1, 2023

Primary Completion Date

September 1, 2026

Study Completion Date

April 1, 2027

Conditions
NSCLCBRAF V600E MutationAdvanced CancerStage IIIB NSCLCStage IV NSCLC
Interventions
DRUG

Combind asprin with Trametinib and Dabrafenib

Treatment drug: Dabrafenib 150 mg BID, Trametinib 2 mg QD, Aspirin 100 mg/tablet, 1 tablet/time, QD

All Listed Sponsors
lead

Daping Hospital and the Research Institute of Surgery of the Third Military Medical University

OTHER

NCT05988697 - Evaluate the Efficacy and Safety of Aspirin in Combination With Trametinib and Dabrafenib | Biotech Hunter | Biotech Hunter